Home » Newsletters » BioWorld Science

BioWorld Science

July 1, 1997

View Archived Issues

Epilepsy monotherapy approved in Canada

Endothelin antagonist protects against indomethacin-induced gastric damage

New hypoglycemic/insulin-sensitizing agent from Novartis

PN-401: a new uridine prodrug from Pro-Neuron

TIMI-IIA finds enoxaparin promising

Modified t-PA from Eisai highly effective thrombolytic

Lidocaine/prilocaine cream effective and safe in neonatal circumcision

MS-322: new centrally acting muscle relaxant with little CNS depressant activity

Neuroprotective effects of NMDA antagonists in animal models

ReoPro safe and effective in high-risk PTCA patients

YM-435 shows promise in acute hypertensive episodes

JTV-506: a potent and selective coronary vasodilator from Japan Tobacco

Preclinical results with Anika's INCERT promising

MDX-210 shows promise in advanced kidney and prostate cancer

Recombinant multiantigen AIDS vaccine enters second phase I trial

Abbott and Metabolex enter diabetes collaboration

DynaGen acquires Superior Pharmaceutical

Cellegy's antiwrinkling product enters clinical trials

Trega Biosciences and Ono to collaborate on melanocortin receptor pathway research

Sequus signs marketing agreement for Amphocil

Schering-Plough and Chiroscience to collaborate on asthma and inflammatory disease treatments

Genzyme and Massachusetts General Hospital to collaborate on gene therapy projects

Algene and Janssen extend collaboration in genetic study of schizophrenia

Cell Genesys reports encouraging preclinical results of gene therapy for hemophilia

Catalytica to acquire Glaxo Wellcome pharmaceutical production facility

Popular Stories

Today's news in brief
BioWorld
ADPD 2026: Can we prevent dementia? Scientists quantify it
BioWorld
Neurodegenerative disease and cognitive decline cannot be explained by a single process. Beta-amyloid plaques, hyperphosphorylated tau, alpha-synuclein, activated...
ADPD 2026: Three inflection points to target Alzheimer’s disease
BioWorld Science
A new way of understanding Alzheimer’s disease, based on biological inflection points that mark decisive moments in the progression of the disorder, could change...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 17, 2026
SERCA inhibitor from Sumitomo shows promise for MSA-C treatment
BioWorld Science
At the ongoing International Conference on Alzheimer’s and Parkinson’s Diseases and Related Neurological Disorders (AD/PD 2026) in Copenhagen, Sumitomo Pharma Co....